BioSpace News Archive

ASLAN Pharmaceuticals announced the presentation of new eblasakimab data at the 2022 European Academy of Dermatology and Venereology annual congress in Milan, Italy.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.

Gerresheimer AG and Stevanato Group S.p.A. announce that they have jointly developed a high-end Ready-To-Use solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology.

Benchling, the R&D Cloud powering the biotechnology industry, launched the industry’s first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that their previously mentioned Advance Safety Needle System™ has entered full scale production on their automated machine.

Stevanato Group S.p.A. and Gerresheimer AG announce that they have jointly developed a high-end Ready-To-Use solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that company management is scheduled to webcast presentations from two upcoming financial conferences.

Isofol Medical AB, reported data from the AGENT study that formed the basis for its assessment that it was not justified to continue the study.

IRLAB Therapeutics AB announced that Richard Godfrey, CEO of IRLAB, will present at Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden, on Thursday, September 8, 2022, at 11:00 am CEST.

“We are excited to announce the addition of two new target indications for batoclimab, one of which will be a pivotal program, confirming our confidence in the broad development opportunity for batoclimab,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.